Biolegend, 345602, Purified anti-human FLT3L Antibody, 100μg

Human FLT3L was initially cloned from a T cell cDNA library using a mouse probe; the human and mouse FLT3L proteins share 72% amino acid identity. FLT3L is synthesized as a type I membrane-bound protein, which is cleaved to become a soluble growth factor. An additional soluble form of FLT3L has been reported as a result of alternative splicing. TACE (ADAM17) plays a key role in the ectodomain shedding of FLT3L. In fact, serum FLT3L levels are decreased in TACE deficient mice. FLT3L is crucial for the development of the two main subsets of dendritic cells (DCs): conventional DCs (cDCs) and plasmacytoid DCs (pDCs). Changes in the development or number of DCs can alter T cell immunity and tolerance. A feedback loop between DCs and Tregs is regulated via FLT3L, as it has been shown that the increase in Tregs induced by DC expansion delays the onset of type 1 autoimmune diabetes and IBD in mice. FLT3L also facilitates formation of Tregs and thus, reduces severity of antigen-induced arthritis in mice. FLT3L deficiency in humans has been shown to result in bone marrow hypoplasia, with low levels of hematopoietic progenitors (particularly myeloid and B cell progenitors). FLT3L is elevated in the synovial fluid of rheumatoid arthritis (RA) patients and FLT3L has been included in panels of preclinical markers for predicting the possible development of RA. The innate sensing pathway triggered by Plasmodium infection regulates DC homeostasis and adaptive immunity via FLT3L release. High levels of FLT3L and increased DCs have been detected in humans and mice during Plasmodium infection.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Human FLT3L transfected cell line.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/mL
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Surface staining in fixed cells may result in lower signal compared to unfixed cells.
RRID: AB_3675066 (BioLegend Cat. No. 345602)
Structure: P49771
Distribution: Hematopoietic precursors, stromal bone marrow cells, T Lymphocytes
Function: FLT3L stimulates the proliferation of hematopoietic precursors and development of B cells and dendritic cells. Additionally, FLT3L is also required for the development of monocytes in humans and NK cells in mice. FLT3L regulates the homeostatic feedback loop between DCs and Tregs.
Interaction: Hematopoietic stem progenitor cells, progenitor cells, DCs, monocytes, B cells, and NK cells
Ligand/Receptor: Fms related receptor tyrosine kinase 3, FLT3, CD135
Cell Type: Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area: Stem Cells
Molecular Family: Cytokines/Chemokines, Growth Factors
Antigen References: Hannum C, et al. 1994. Nature. 368:643-8. Waskow C. 2008. Nat Immunol. 9:676-83. Darrasse-Jèse G, et al. 2009. J Exp Med. 206:1853-62. Horiuchi K, et al. 2009. J Immunol. 182:7408-14. Svensson MN, et al. 2013. PLoS One. 8:e54884. Guermonprez P, et al. 2013. Nat Med. 19:730-8. Chklovskaia E, et al. 2001. Blood. 97:1027-34. Momenilandi M, et al. 2024. Cell. 187:2817.
Gene ID: 2323
UniProt: View information about FLT3L on UniProt.org
Clone: W19353A
Regulatory Status: RUO
Other Names: FLT3LG, Fms related receptor tyrosine kinase 3 ligand, Fms-like tyrosine kinase 3 ligand, Flt3 Ligand, SL cytokine
Isotype: Rat IgG2a, κ